Xenon Pharmaceuticals Q2 2024 GAAP EPS $(0.75) Misses $(0.70) Estimate
Portfolio Pulse from Benzinga Newsdesk
Xenon Pharmaceuticals (NASDAQ:XENE) reported a Q2 2024 GAAP EPS of $(0.75), missing the analyst consensus estimate of $(0.70) by 7.14%.
August 08, 2024 | 8:52 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Xenon Pharmaceuticals reported a Q2 2024 GAAP EPS of $(0.75), missing the analyst consensus estimate of $(0.70) by 7.14%.
The reported EPS miss indicates that the company's performance was below market expectations, which is likely to negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100